AstraZeneca



AstraZeneca CEO says lung cancer drug trial data ‘very encouraging’

  • The drugmaker’s shares fell by as much as 8 percent earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01
  • The company said on Friday it will continue with its plan to file data from the trial with FDA
By Reuters ·

Special

Indonesia halts use of AstraZeneca vaccine batch for toxicity tests

By Ismira Lutfia Tisnadibrata  ·